Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to -$256919.0.

  • Lexaria Bioscience's Other Working Capital Changes rose 6545.38% to -$256919.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $431464.0, marking a year-over-year increase of 3837.4%. This contributed to the annual value of -$55313.0 for FY2025, which is 10862.87% down from last year.
  • Per Lexaria Bioscience's latest filing, its Other Working Capital Changes stood at -$256919.0 for Q4 2025, which was up 6545.38% from $309156.0 recorded in Q3 2025.
  • Lexaria Bioscience's 5-year Other Working Capital Changes high stood at $808271.0 for Q3 2024, and its period low was -$743696.0 during Q4 2024.
  • Over the past 5 years, Lexaria Bioscience's median Other Working Capital Changes value was -$21150.0 (recorded in 2022), while the average stood at $7744.2.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first crashed by 132590.42% in 2021, then surged by 385828.2% in 2023.
  • Lexaria Bioscience's Other Working Capital Changes (Quarter) stood at -$82030.0 in 2021, then crashed by 285.74% to -$316419.0 in 2022, then tumbled by 30.99% to -$414472.0 in 2023, then tumbled by 79.43% to -$743696.0 in 2024, then surged by 65.45% to -$256919.0 in 2025.
  • Its Other Working Capital Changes was -$256919.0 in Q4 2025, compared to $309156.0 in Q3 2025 and -$27038.0 in Q2 2025.